VivoSeq
Cardiovascular

Cardioversion

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Cardioversion is an early-stage landscape with 0 programs across 2 companies. The most active players are Sanofi, Elpen Pharmaceutical Co. Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

25/100

Attrition Rate

60/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalE

Elpen Pharmaceutical Co. Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Terminated2 · 40%
Completed1 · 20%
Unknown status1 · 20%
Withdrawn1 · 20%

Clinical Trials

Trial Activity

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF
Terminated·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT01805960·24 enrolled
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
Terminated·Sanofi logoSanofi·Phase 4·NCT01026090·292 enrolled
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
Completed·WWake Forest University Health Sciences·Phase 4·NCT04187196·73 enrolled
Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm
Unknown status·—·N/A·NCT01266681·100 enrolled
COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF
Withdrawn·EElpen Pharmaceutical Co. Inc.·Phase 3·NCT02582190

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)